Gilead Sciences, Inc. (Nasdaq:GILD) announced today the
appointment of Norbert W. Bischofberger, PhD to the position of
Executive Vice President, Research and Development and Chief
Scientific Officer and the appointment of John F. Milligan, PhD to the
position of Chief Operating Officer.
Dr. Bischofberger joined Gilead in 1990 from Genentech, Inc. He
has held roles of increasing responsibility within the Research and
Development organization at Gilead, and was most recently appointed
Executive Vice President, Research and Development in 2000. He
received his PhD in Organic Chemistry at Eidgenossische Technische
Hochschule in Zurich, Switzerland. As Chief Scientific Officer, Dr.
Bischofberger will oversee all aspects of Gilead's research and
development efforts, including Gilead's recently acquired Seattle,
Washington and Westminster, Colorado programs in the fields of
respiratory and cardiopulmonary therapeutics and the company's
Edmonton, Alberta operations. A. Bruce Montgomery, MD, Senior Vice
President, Head of Respiratory Therapeutics will now report to Dr.
Bischofberger.
Dr. Milligan also joined Gilead in 1990, beginning his career at
the company as a Research Scientist. He has held leadership roles in
Project Management and Corporate Development. Dr. Milligan was
appointed Senior Vice President and Chief Financial Officer in 2002
and was promoted to Executive Vice President in 2003. He received a
Doctorate in Biochemistry from the University of Illinois and was an
American Cancer Society Postdoctoral fellow at the University of
California at San Francisco. In his new role, Dr. Milligan will
oversee Gilead's commercial organization, manufacturing, finance and
business operations. Kevin Young, Executive Vice President, Commercial
Operations will continue to lead Gilead's commercial organization,
which he has grown substantially since joining the company in 2004,
and will report in this role to Dr. Milligan. Anthony Caracciolo,
Senior Vice President, Manufacturing will also report to Dr. Milligan.
Dr. Milligan will continue to serve in the role of Chief Financial
Officer until a new CFO is identified.
"Gilead has grown tremendously over the last several years, and
these organizational changes will ensure our company is positioned to
continue delivering new, innovative therapies to those patients most
in need," said John C. Martin, PhD, President and Chief Executive
Officer, Gilead Sciences. "I am confident in the abilities of Gilead's
senior leadership team - Norbert, John, Kevin, Gregg Alton, Senior
Vice President and General Counsel and Kristen Metza, Vice President,
Human Resources - to guide the continued success of our company."
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of unmet
medical need. The company's mission is to advance the care of patients
suffering from life-threatening diseases worldwide. Headquartered in
Foster City, California, Gilead has operations in North America,
Europe and Australia.
For more information on Gilead, please call the Gilead Public
Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit
www.gilead.com.
